Skip to main content
Mariasilvia Guardiani on Muck Rack

Mariasilvia Guardiani

As seen in: Nature, Wiley Online Library, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mariasilvia

Contact Mariasilvia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-Acting Cabotegravir/Rilpivirine Reduces Immune-Activation and -Senescence in People With HIV With CMV Co-Infection

|
By Mariasilvia Guardiani, Infectious Diseases Sapienza, NESMOS Sapienza
| Wiley Online Library Verified
1 Introduction The introduction of Long Acting (LA) injectable drugs in the context of HIV infection represents one of the major pharmacological innovations of the last 20 years and constitutes a new paradigm in the administration of therapy [1, 2]. The first two available drugs of this new category, Cabotegravir/Rilpivirine (CAB/RPV)-LA, have demonstrated noninferiority in maintaining virological suppression, compared with oral therapy [2-6].
Open in Who Shared Issue with article?

Dynamic changes of monocytes-related immune activation in people with HIV switching to long-acting injectable cabotegravir plus rilpivirine

|
By Maria Antonella Zingaropoli, Mariasilvia Guardiani, Anna Carraro, Eeva Tortellini, Federica Dominelli, Michele Antonacci, Cosmo Del Borgo, Raffaella Marocco, Giulia Mancarella, Serena Vita, Fabio Mengoni, Roberta Campagna, Ombretta Turriziani, Miriam Lichtner, Lorenzo Ansaldo, Piergiorgio Pace, Livia Bresciani, Maria Rosa Ciardi, Claudio Mastroianni Mastroianni
| Nature Verified
Abstract The aim of this study was to examine the dynamic changes in monocyte/macrophage- and dendritic cell (DC)-related immune activation in people with HIV (PWH) before switching to long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) (T0), after six (T6m) and twelve months (T12m). A total of 30 aviremic PWH switching to LA CAB plus RPV, and 32 healthy donors (HDs) were enrolled.
Open in Who Shared Issue with article?

The Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients

|
By Maria Antonella Zingaropoli, Mariasilvia Guardiani, Federica Dominelli, Eeva Tortellini
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (427) Issue with article?
See all 4 articles